AAAAAA

   
Results: 1-7 |
Results: 7

Authors: Gajjar, DA LaCreta, FP Uderman, HD Kollia, GD Duncan, G Birkhofer, MJ Grasela, DM
Citation: Da. Gajjar et al., A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men, PHARMACOTHE, 20(6), 2000, pp. 49S-58S

Authors: LaCreta, FP Kaul, S Kollia, GD Duncan, G Randall, DM Grasela, DM
Citation: Fp. Lacreta et al., Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults, PHARMACOTHE, 20(6), 2000, pp. 59S-66S

Authors: LaCreta, FP Kollia, GD Duncan, G Behr, D Grasela, DM
Citation: Fp. Lacreta et al., Age and gender effects on the pharmacokinetics of gatifloxacin, PHARMACOTHE, 20(6), 2000, pp. 67S-75S

Authors: Gajjar, DA LaCreta, FP Kollia, GD Stolz, RR Berger, S Smith, WB Swingle, M Grasela, DM
Citation: Da. Gajjar et al., Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise, PHARMACOTHE, 20(6), 2000, pp. 76S-86S

Authors: Grasela, DM Christofalo, B Kollia, GD Duncan, G Noveck, R Manning, JA LaCreta, FP
Citation: Dm. Grasela et al., Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment, PHARMACOTHE, 20(6), 2000, pp. 87S-94S

Authors: Grasela, DM LaCreta, FP Kollia, GD Randall, DM Uderman, HD
Citation: Dm. Grasela et al., Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers, PHARMACOTHE, 20(3), 2000, pp. 330-335

Authors: Macaulay, VM O'Byrne, KJ Green, JA Philip, PA McKinley, L LaCreta, FP Winograd, B Ganesan, TS Harris, AL Talbot, DC
Citation: Vm. Macaulay et al., Phase I study of the mitomycin C analogue BMS-181174, BR J CANC, 77(11), 1998, pp. 2020-2027
Risultati: 1-7 |